WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Ukrainian president orders demobilization of conscriptsJohn Sterling honored by Yankees for 36 seasons and 5,631 games as radio voiceIndonesian police arrest 8 suspected militants, part of a banned extremist group with alSarah Nurse scores in OT to lift Toronto over Montreal 3North Carolina's Harrison Ingram opts to enter the NBA draftKitty set out to have casual sex for a year to see if women really can have noRennes routs Nantes 3The monkey gangs turning this Thai city into a realFrancisco Lindor slugs tiebreaking 2North Korea says it tested 'super